DE602004028469D1 - APPLICATIONS FROM IT - Google Patents
APPLICATIONS FROM ITInfo
- Publication number
- DE602004028469D1 DE602004028469D1 DE602004028469T DE602004028469T DE602004028469D1 DE 602004028469 D1 DE602004028469 D1 DE 602004028469D1 DE 602004028469 T DE602004028469 T DE 602004028469T DE 602004028469 T DE602004028469 T DE 602004028469T DE 602004028469 D1 DE602004028469 D1 DE 602004028469D1
- Authority
- DE
- Germany
- Prior art keywords
- cholesterol
- fragment
- variant
- derivative
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 7
- 235000012000 cholesterol Nutrition 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- OKZYCXHTTZZYSK-ZCFIWIBFSA-N (R)-5-phosphomevalonic acid Chemical compound OC(=O)C[C@@](O)(C)CCOP(O)(O)=O OKZYCXHTTZZYSK-ZCFIWIBFSA-N 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 abstract 1
- 239000006227 byproduct Substances 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Insects & Arthropods (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Peptides Or Proteins (AREA)
Abstract
An isolated peptide comprising the amino acid sequence of SEQ ID NO: 2, or a variant, derivative and/or fragment thereof having the function of HMGCoA reductase inhibitor, phosphomevalonate inhibitor, reducing the accumulation of cholesterol in the cholesterol biosynthesis pathway and/or reducing the level of serum cholesterol. Also disclosed is a pharmaceutical composition comprising the peptide having sequence SEQ ID NO:2 or a variant, derivative and/or fragment thereof. Also disclosed is a method for treatment or prophylaxis of disorders characterised by the accumulation of cholesterol, its by-products and/or related lipid derived products, comprising administering to a subject in need at least one peptide comprising the amino acid sequence of SEQ ID NO: 2, or a variant, derivative and/or fragment thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47620803P | 2003-06-05 | 2003-06-05 | |
| PCT/SG2004/000168 WO2004108928A1 (en) | 2003-06-05 | 2004-06-04 | Cholesterol biosynthesis pathway modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004028469D1 true DE602004028469D1 (en) | 2010-09-16 |
Family
ID=33511764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004028469T Expired - Lifetime DE602004028469D1 (en) | 2003-06-05 | 2004-06-04 | APPLICATIONS FROM IT |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060222638A1 (en) |
| EP (1) | EP1636365B1 (en) |
| AT (1) | ATE476506T1 (en) |
| DE (1) | DE602004028469D1 (en) |
| WO (1) | WO2004108928A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| US5902805A (en) * | 1996-04-22 | 1999-05-11 | L'oreal | Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same |
-
2004
- 2004-06-04 AT AT04736173T patent/ATE476506T1/en not_active IP Right Cessation
- 2004-06-04 WO PCT/SG2004/000168 patent/WO2004108928A1/en active Search and Examination
- 2004-06-04 DE DE602004028469T patent/DE602004028469D1/en not_active Expired - Lifetime
- 2004-06-04 EP EP04736173A patent/EP1636365B1/en not_active Expired - Lifetime
- 2004-06-04 US US10/559,649 patent/US20060222638A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004108928A1 (en) | 2004-12-16 |
| ATE476506T1 (en) | 2010-08-15 |
| EP1636365A1 (en) | 2006-03-22 |
| EP1636365B1 (en) | 2010-08-04 |
| US20060222638A1 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nongonierma et al. | Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis | |
| Fan et al. | Identification and characterization of gastrointestinal-resistant angiotensin-converting enzyme inhibitory peptides from egg white proteins | |
| Bastos et al. | Prolyl oligopeptidase of Trypanosoma brucei hydrolyzes native collagen, peptide hormones and is active in the plasma of infected mice | |
| EA200401471A1 (en) | APPLICATION OF CETR INHIBITORS AND POSSIBLE INHIBITORS OF HMG COA AND / OR ANTIHYPERTENSIVE AGENTS | |
| NO20012984L (en) | Succinoylamino benzodiazepines as inhibitors of AB protein production | |
| BR9908280A (en) | Phospholipase enzyme inhibitors | |
| ATE232873T1 (en) | PHOSPHONIC ACID DERIVATIVES AS PTP-1B INHIBITORS | |
| MA30975B1 (en) | PARENTERAL FORMULATION OF ABETA ANTI-PEPTIDE ANTIBODY | |
| IL175319A (en) | Phosphate-binding protein, compositions comprising it, use thereof and method for detecting the same | |
| Taddese et al. | MMP-12 catalytic domain recognizes and cleaves at multiple sites in human skin collagen type I and type III | |
| IL193771A (en) | Compositions having cholesteryl ester transfer protein inhibitory activity | |
| IL159960A (en) | Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments | |
| Guggi et al. | In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases | |
| WO2002038742A3 (en) | Dipeptidylpeptidases and methods of use | |
| EP2039367A4 (en) | Prophylactic/therapeutic agent for neurodegenerative disease | |
| Taddese et al. | In vitro degradation of human tropoelastin by MMP-12 and the generation of matrikines from domain 24 | |
| AU5799200A (en) | Lpl variant therapeutics | |
| WO2003107009A3 (en) | Methods for improving a binding characteristic of a molecule | |
| WO2003035679A3 (en) | Molecules | |
| WO2008047370A3 (en) | Compositions and methods for inducing angiogenesis | |
| SG170109A1 (en) | Proteins, nucleic acids and medicaments | |
| WO1998051665A3 (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
| WO2003105753A3 (en) | Targeted enzymes and methods of making and using targeted enzymes. | |
| DE602004028469D1 (en) | APPLICATIONS FROM IT | |
| WO2004096832A3 (en) | Novel antiangiogenic peptides |